רנקסה 1000 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

RANOLAZINE 1000 MG

Disponibbli minn:

NEOPHARM LTD

Kodiċi ATC:

C01EB18

Għamla farmaċewtika:

TABLETS EXTENDED RELEASE

Rotta amministrattiva:

PER OS

Manifatturat minn:

CV THERAPEUTICS INC, USA

Grupp terapewtiku:

RANOLAZINE

Indikazzjonijiet terapewtiċi:

Ranexa is indicated for the treatment of chronic angina. Ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.

Data ta 'l-awtorizzazzjoni:

2010-10-01